NO PRIOR AUTHORIZATION FOR CERTAIN DRUGS

SB 477 prohibits health insurers in New Mexico from requiring prior authorization or step therapy (forcing patients to try cheaper drugs first) for specific prescription medications. It directly affects patients with autoimmune disorders, cancer, cholesterol issues, or substance use disorders, and those prescribed medications in three drug classes: GLP-1 agonists (used for diabetes/weight management), glucose-dependent insulinotropic polypeptide, and GLP-1 receptor agonists. Insurers may still require authorization only if a biosimilar, interchangeable biologic, or generic version of the drug is available. The bill aims to streamline access to these treatments by removing bureaucratic barriers, but it remains pending after being postponed indefinitely in June 2025.